Showing 39,961 - 39,980 results of 80,813 for search '(( 2 c decrease ) OR ( 5 ((((step decrease) OR (mean decrease))) OR (nn decrease)) ))', query time: 1.35s Refine Results
  1. 39961

    Data_Sheet_1_LncRNA NBR2 Inhibits the Malignancy of Thyroid Cancer, Associated With Enhancing the AMPK Signaling.docx by Wen Yang (235745)

    Published 2020
    “…Furthermore, treatment with A-769662 (a specific AMPK activator), like NBR2 over-expression, significantly attenuated the malignancy of BHT101 cells while treatment with Compound C (a specific AMPK inhibitor) significantly rescued that NBR2-reduced malignancy of BHT101 cells. …”
  2. 39962
  3. 39963

    Image_2_Knockdown of LMTK3 in the Endometrioid Adenocarcinoma Cell Line Ishikawa: Inhibition of Growth and Estrogen Receptor α.tif by Guiyang Cai (11584636)

    Published 2021
    “…There was a positive correlation between the mRNA expression levels of LMTK3 and ESR1 (Spearman: P=2.011e-5, R=0.13; Pearson: P=7.18e-8, R=0.17). …”
  4. 39964

    Table_2_Pharmacokinetics and Pharmacodynamics of a Novel Virulent Klebsiella Phage Kp_Pokalde_002 in a Mouse Model.docx by Gunaraj Dhungana (11276481)

    Published 2021
    “…A higher concentration of phage in plasma was found after 4 h (2.3 x 10<sup>5</sup> PFU/ml) and 8 h (7.3 x 10<sup>4</sup> PFU/ml) of administration through IP and oral route, respectively. …”
  5. 39965

    Image_2_Pharmacokinetics and Pharmacodynamics of a Novel Virulent Klebsiella Phage Kp_Pokalde_002 in a Mouse Model.jpeg by Gunaraj Dhungana (11276481)

    Published 2021
    “…A higher concentration of phage in plasma was found after 4 h (2.3 x 10<sup>5</sup> PFU/ml) and 8 h (7.3 x 10<sup>4</sup> PFU/ml) of administration through IP and oral route, respectively. …”
  6. 39966

    Data_Sheet_1_LncRNA NBR2 Inhibits the Malignancy of Thyroid Cancer, Associated With Enhancing the AMPK Signaling.docx by Wen Yang (235745)

    Published 2021
    “…Furthermore, treatment with A-769662 (a specific AMPK activator), like NBR2 over-expression, significantly attenuated the malignancy of BHT101 cells while treatment with Compound C (a specific AMPK inhibitor) significantly rescued that NBR2-reduced malignancy of BHT101 cells. …”
  7. 39967

    DataSheet1_SMARCC1 Enters the Nucleus via KPNA2 and Plays an Oncogenic Role in Bladder Cancer.ZIP by Zhengmao Wei (12571393)

    Published 2022
    “…</p><p>Results: In our experiments, Spearman’s correlation analysis, immunofluorescence staining and co-immunoprecipitation (Co-IP) assays showed that SMARCC1 interacted with KPNA2, and after knockdown of KPNA2, Nup50 and Nup153, the nuclear content of SMARCC1 decreased while the amount of SMARCC1 protein remaining in the cytoplasm increased, indicating that SMARCC1 could be transported into the nucleus via KPNA2 and thus acted as an oncogene. …”
  8. 39968

    <i>Rpl5</i> mutant ES cells exhibit a p53-independent G2 cell cycle arrest. by Sharon A. Singh (524066)

    Published 2014
    “…In contrast, the cell cycle profile of the <i>Rpl5</i> mutant ES cells exhibited a three-fold increase in the G2 phase with a concomitant decrease in the G1 and S phases, consistent with a delayed G2 phase transition (A, C) (three independent pooled experiments). …”
  9. 39969

    RPIA regulates colon cell proliferation through β-catenin expression in HCT116 cells. by Yu-Ting Chou (447778)

    Published 2018
    “…(G) Knockdown of RPIA decreased the mRNA levels of the β-catenin target genes <i>CCND1</i>, <i>CCNE2</i>, and <i>AXIN2</i> in HCT116 cells. …”
  10. 39970

    Image_2_Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation.JPEG by Huimin Deng (1844299)

    Published 2018
    “…In vitro experiments showed that B. fragilis inhibited C. difficile adherence, and attenuated the decrease in CDI-induced transepithelial electrical resistance, ZO-1 and MUC-2 loss, and apoptosis, suggesting that B. fragilis protected against CDI possibly by resisting pathogen colonization and improving gut barrier integrity and functions. …”
  11. 39971

    Image_2_Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation.JPEG by Huimin Deng (1844299)

    Published 2019
    “…In vitro experiments showed that B. fragilis inhibited C. difficile adherence, and attenuated the decrease in CDI-induced transepithelial electrical resistance, ZO-1 and MUC-2 loss, and apoptosis, suggesting that B. fragilis protected against CDI possibly by resisting pathogen colonization and improving gut barrier integrity and functions. …”
  12. 39972
  13. 39973
  14. 39974
  15. 39975

    DataSheet2_Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction.xlsx by Liyun Zhang (280172)

    Published 2021
    “…We also observed elevated M1 macrophages and decreased M2 macrophages, which were exhibited by increased mRNA expression of M1 markers (iNOS, CD86, and CD80) and decreased mRNA expression of M2 markers (Arg1, CD163, and CD206) in HFpEF hearts. …”
  16. 39976

    DataSheet2_Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction.xlsx by Liyun Zhang (280172)

    Published 2022
    “…We also observed elevated M1 macrophages and decreased M2 macrophages, which were exhibited by increased mRNA expression of M1 markers (iNOS, CD86, and CD80) and decreased mRNA expression of M2 markers (Arg1, CD163, and CD206) in HFpEF hearts. …”
  17. 39977

    <i>In Vivo</i> Evolution of Bacterial Resistance in Two Cases of <i>Enterobacter aerogenes</i> Infections during Treatment with Imipenem by Nadège Philippe (253294)

    Published 2015
    “…These were <i>omp35</i> and <i>omp36</i>, encoding the two major porins; <i>rob</i>, encoding a global AraC-type transcriptional activator; <i>cpxA, phoQ</i> and <i>pmrB</i>, encoding sensor kinases of the CpxRA, PhoPQ and PmrAB two-component regulatory systems, respectively. …”
  18. 39978

    Supplementary file 2_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

    Published 2025
    “…TDM significantly improved treatment efficacy (RR = 1.19; 95% CI: 1.10–1.28) and bacterial clearance rates (RR = 1.29; 95% CI: 1.12–1.48). CRP levels decreased significantly (mean difference = 14.91; 95% CI: 2.79–27.02), while changes in PCT, WBC, and neutrophil ratios were non-significant. …”
  19. 39979
  20. 39980